Answer
Dabrafenib targets abnormal BRAF signalling and is not suitable for the selected licensed cancers unless the relevant BRAF V600 mutation is confirmed.
Sources for this answer
- Tafinlar 50 mg & 75 mg hard capsules — Current selected SmPCemc · Summary of Product Characteristics
- Finlee 10 mg dispersible tablets — Current selected SmPCemc · Summary of Product Characteristics
General medicine information. Follow the instructions for your own medicine and speak to a pharmacist or clinician about your individual circumstances.